Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2013 February;54(1) > The Journal of Cardiovascular Surgery 2013 February;54(1):115-22

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

ORIGINAL ARTICLES  VASCULAR SECTION Freefree

The Journal of Cardiovascular Surgery 2013 February;54(1):115-22

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup

Bosiers M. 1, Peeters P. 2, Tessarek J. 3, Deloose K. 1, Strickler S. 4

1 Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium; 2 Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium; 3 Department of Vascular Surgery, St Bonifatius Hospital, Lingen, Germany; 4 MED Institute, Inc., West Lafayette, Indiana, USA


PDF


Aim: The aim of the present article was to report the 12-month results of the Zilver® PTX® Single Arm StudyTASC C/D de novo lesion subgroup.
Methods: The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding nitinol stent with a polymer-free paclitaxel coating. This is a prospective, single-arm, multicentre clinical study evaluating the Zilver PTX Drug-Eluting Peripheral Stent for treating patients with symptomatic lesions in the above-the-knee femoropopliteal artery. This study enrolled 787 patients (900 lesions) with Rutherford class 2 or higher treated with the Zilver PTX stent; 135 were long de novo lesions, corresponding to TASC II Class C or D.
Results: The 135 long lesions had a mean length of 226.1±43.6 mm. The 12-month Kaplan-Meier estimates included a 77.6% primary patency rate, an 84.7% event-free survival rate, and an 85.4% rate of freedom from target lesion revascularization (TLR). The 12-month stent fracture rate was 2.1%.
Conclusion: The primary patency rates in the analysis of the TASC C/D de novo lesion subgroup of the Zilver PTX Single Arm Study indicate that endovascular therapy outcomes with a paclitaxel eluting stent may equal those of bypass surgery. Endovascular treatment with DES may play an important role for treatment of patients who present with TASC C or D femoropopliteal lesions.

inizio pagina